Covishield, Covaxin Effective Against 'Indian Strain' Of Coronavirus: Study

Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology (IGIB), said post vaccination, the infections are milder.

Covishield and Covaxin -- the two coronavirus vaccines currently in use in India -- have efficacy against the "Indian strain" and show "milder" illness in case of infection post vaccination, a senior scientist said on Tuesday citing preliminary results of a study. Anurag Agrawal, the Director of the Institute of Genomics and Integrative Biology (IGIB), said the study on effectiveness of the available vaccines on the B.1.617 variant of SARS-CoV2 suggests that post vaccination, the infections are milder. The B.1.617 variant is also being called a ''double mutant'' or the ''Indian strain''. "Initial positive neutralisation studies of B.1.617, with both post-Covaxin or Covishield sera, are correlatable with milder disease during post-vaccination breakthrough infections. This is a positive while we get quantitative data for better understanding of infection protection," Mr Agrawal tweeted.